A deliberately cautious review of low-dose rapamycin in healthy adults, and re-models one cohort using the PhenoAge biological-aging clock. Verdict: despite strong animal lifespan data, human evidence does NOT yet prove rapamycin delays aging in healthy people. A valuable counterweight to longevity-community hype - it holds the human evidence to a strict standard rather than over-reading promising signals.
| Evidence tier | D Mechanistic / in vitro / review |
| Study type | Narrative Review |
| Model system | Narrative review + PhenoAge modeling of one cohort |
| Journal | Aging (Albany NY) |
| Year | 2025 |
| Peer reviewed | Yes |
| Source | DOI 10.18632/aging.206300 · PMID 40778880 · Free full text (PMC12422820) |
Low dose rapamycin therapy has been proposed as a longevity candidate in healthy aging adults. We present a review of the evidence for low dose rapamycin and rapalog therapies in healthy human adults and model the findings of one cohort study using the PhenoAge model. Despite the preclinical evidence supporting the use of sirolimus to enhance mean and maximal lifespan, the data in humans have yet to establish that rapamycin, or its analogues, is a proven seno-therapeutic that can delay aging in healthy older adults. Rapamycin and rapalogs warrant further study with larger cohorts to better establish their contribution to human aging.
| Intervention | Not applicable (narrative review + PhenoAge modeling) |
| Target | mTOR |
| Model | Narrative review (+ modeling of one cohort) |
| Effect | Reviews the limited human evidence for off-label low-dose rapamycin in healthy adults; benefit not yet established |